Day 2 Program

Translational Controversies: ADCs, Targeted Therapy, or Chemo?

Day 2: December 10, 2025

1:00 PM–2:15 PM CST

Stars at Night 3-4

Session Details

This session examines the evolving role of antibody-drug conjugates (ADCs) in breast cancer, debating whether they function primarily as targeted therapies or as chemotherapy, with insights from pathology and clinical evidence.

CT1-01

HER2 low/ultralow: what the pathologist sees

Dennis Sgroi, Massachusetts General Hospital, Boston, MA

CT1-02

Evidence that ADCs are targeted therapy

Sarat Chandarlapaty, Memorial Sloan Kettering Cancer Center, New York, NY

CT1-03

Evidence that ADCs are chemotherapy

Sara A Hurvitz, Fred Hutchinson Cancer Center, Bellevue, WA